PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.

Nedlands-based biotech company PYC Therapeutics has received approvals to start human trials over a drug candidate for kidney ...

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her ...

Besides zorevunersen, STOK is also looking to develop another candidate, STK-002, for the treatment of autosomal dominant optic atrophy. Stoke Therapeutics currently has a Zacks Rank #2 (Buy).